| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant Systemic Treatment for Women with Breast Cancer: The Future of Clinical Trials
|
Goldhirsch, A.
|
|
2011
|
47 |
S2 |
p. 1-2
2 p.
|
artikel
|
| 2 |
A Double-blind, Randomized Phase lib Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared to Placebo (PL) When Administered in Combination with Docetaxel And/or Letrozole in Patients with Metastatic Breast Cancer (MBC): FM-B07-01 Trial
|
Mariani, G.
|
|
2011
|
47 |
S2 |
p. 10-
1 p.
|
artikel
|
| 3 |
A Multicentre Randomised Trial of Ibandronate Compared to Single Dose Radiotherapy for Localised Metastatic Bone Pain in Prostate Cancer (RIB)
|
Hoskin, P.
|
|
2011
|
47 |
S2 |
p. 6-
1 p.
|
artikel
|
| 4 |
A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With Placebo (PBO) When Administered in Combination With Chemotherapy (Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With Metastatic Colorectal Cancer (mCRC). The RESPECT Trial
|
Tabernero, J.
|
|
2011
|
47 |
S2 |
p. 11-
1 p.
|
artikel
|
| 5 |
A Phase II Study of Sorafenlb In Patients with Locally Advanced And/or Metastatic (stage 1MB or IV) Non-small Cell Lung Cancer (NSCLC) with a K-Ras Mutation
|
Dinqemans, A.M.
|
|
2011
|
47 |
S2 |
p. 14-
1 p.
|
artikel
|
| 6 |
A Phase l/lI, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer
|
Van Cutsem, E.
|
|
2011
|
47 |
S2 |
p. 8-9
2 p.
|
artikel
|
| 7 |
A Pivotal Multicenter Trial Evaluating Efficacy and Safety of the Hedgehog Pathway Inhibitor (HPI) Vismodegib in Patients With Advanced Basal Cell Carcinoma (BCC)
|
Dirix, L.
|
|
2011
|
47 |
S2 |
p. 2-
1 p.
|
artikel
|
| 8 |
A Randomized Clinical Trial of Adjuvant Chemotherapy with Doxorubicin, Ifosfamide, and Cisplatin in Localized Uterine Sarcomas. Results On 81 Randomized Patients
|
Pautier, P.
|
|
2011
|
47 |
S2 |
p. 15-
1 p.
|
artikel
|
| 9 |
AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev + Pemetrexed (pern) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx)
|
Barlesi, F
|
|
2011
|
47 |
S2 |
p. 16-
1 p.
|
artikel
|
| 10 |
Blood Pressure and Risk of Incident and Fatal Cancer in the Metabolic Syndrome and Cancer Project (Me-Can) — Analysis of Seven Prospective Cohorts
|
Van Hemelrijck, M.
|
|
2011
|
47 |
S2 |
p. 3-
1 p.
|
artikel
|
| 11 |
Celecoxib Plus Hormone Therapy Vs Hormone Therapy Alone for Hormone-sensitive Prostate Cancer: First Results From the STAMPEDE Randomised Controlled Trial (MRC PR08)
|
James, N.D.
|
|
2011
|
47 |
S2 |
p. 11-
1 p.
|
artikel
|
| 12 |
Clinical, Molecular, and Molecular-Clinical Profile (MCP) Exploratory Subset Analysis of RTOG 0525: a Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-dense (dd) Schedule for Glioblastoma (GBM)
|
Mehta, M.
|
|
2011
|
47 |
S2 |
p. 10-
1 p.
|
artikel
|
| 13 |
Cognitive and Cardiac Outcome After Prenatal Exposure to Chemotherapy in Children 18 Months or Older
|
Amant, F.
|
|
2011
|
47 |
S2 |
p. 8-
1 p.
|
artikel
|
| 14 |
Delivering Affordable Cancer Care in High-income Countries: a Lancet Oncology Commission
|
Sullivan, R.
|
|
2011
|
47 |
S2 |
p. 6-
1 p.
|
artikel
|
| 15 |
Denosumab Treatment for Giant Cell Tumor of Bone (GCTB) in Adolescent Patients: Interim Results From a Phase II Study
|
Enqellau, J.
|
|
2011
|
47 |
S2 |
p. 15-16
2 p.
|
artikel
|
| 16 |
Drugging the Undruggable Small-molecule Inhibition of Ras Oncoprotein
|
Fang, G.
|
|
2011
|
47 |
S2 |
p. 9-
1 p.
|
artikel
|
| 17 |
Efficacy in Patient Subgroups in OCEANS, a Randomized, Double-blinded, Placebo-controlled, Phase 3 Trial of Chemotherapy ± Bevacizumab in Patients with Platinum-sensitive Recurrent Epithelial Ovarian (OC), Primary Peritoneal (PPC), or Fallopian Tube Cancer (FTC)
|
Aghajanian, C.
|
|
2011
|
47 |
S2 |
p. 5-
1 p.
|
artikel
|
| 18 |
Efficacy of Veliparib (ABT-888) Plus Temozolomide Versus Temozolomide Alone: a Randomized, Double-blind, Placebo-controlled Trial in Patients with Metastatic Melanoma
|
Middleton, M.
|
|
2011
|
47 |
S2 |
p. 8-
1 p.
|
artikel
|
| 19 |
Escalated-dose Conformai Radiotherapy for Localised Prostate Cancer: Long-term Overall Survival Results From the MRC RT01 Randomised Controlled Trial
|
Dearnaley, D.P.
|
|
2011
|
47 |
S2 |
p. 11-12
2 p.
|
artikel
|
| 20 |
Evaluation of Individual Codon 12 and 13 Mutant (MT) KRAS Alleles as Prognostic and Predictive Biomarkers of Response to Panitumumab (pmab) in Patients with Metastatic Colorectal Cancer (mCRC)
|
Peeters, M.
|
|
2011
|
47 |
S2 |
p. 16-
1 p.
|
artikel
|
| 21 |
Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial
|
Baselqa, J.
|
|
2011
|
47 |
S2 |
p. 6-7
2 p.
|
artikel
|
| 22 |
Everolimus in Subependymal Giant Cell Astrocytomas (SEGA) Associated with Tuberous Sclerosis Complex (TSC): Results of EXIST-1, a Double-Blind Placebo-controlled Phase III Trial
|
Bebin, M.
|
|
2011
|
47 |
S2 |
p. 4-5
2 p.
|
artikel
|
| 23 |
Identification of Novel Somatic Mutations in SF3B1, a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts and Other Common Cancers
|
Papaemmanuil, E.
|
|
2011
|
47 |
S2 |
p. 7-
1 p.
|
artikel
|
| 24 |
Laparoscopic Surgery Versus Open Surgery for Rectal Cancer: Short-term Outcomes of a Randomised Trial
|
Bonjer, H.J.
|
|
2011
|
47 |
S2 |
p. 4-
1 p.
|
artikel
|
| 25 |
Mutation and Protein Expression Biomarkers Correlate with Response to AKT Inhibition in a Phase I Trial of the Oral Pan AKT Inhibitor GSK2141795 (GSK795) in Patients (pts) with Platinum Resistant Ovarian Cancer
|
Gunqor, H.
|
|
2011
|
47 |
S2 |
p. 12-13
2 p.
|
artikel
|
| 26 |
New therapeutic avenues in lung cancer based on disturbances in PI3K and RAS pathways
|
Rosell, R.
|
|
2011
|
47 |
S2 |
p. 1-
1 p.
|
artikel
|
| 27 |
Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)
|
Parker, C.
|
|
2011
|
47 |
S2 |
p. 3-
1 p.
|
artikel
|
| 28 |
Quality of Life in the ICON7 GCIG Phase III Randomised Clinical Trial
|
Stark, D.
|
|
2011
|
47 |
S2 |
p. 12-
1 p.
|
artikel
|
| 29 |
Quality of Life Outcomes of a Randomized, Placebo-Controlled Trial of Bevacizumab in the Front-Line Treatment of Ovarian Cancer: a Gynecologic Oncology Group Study
|
Monk, B.J.
|
|
2011
|
47 |
S2 |
p. 12-
1 p.
|
artikel
|
| 30 |
Response to Imatinib Rechallenge of GIST That Recurs Following Completion of Adjuvant Imatinib Treatment - the First Analysis in the SSGXVIII/AIO Trial Patient Population
|
Reichardt, P.
|
|
2011
|
47 |
S2 |
p. 15-
1 p.
|
artikel
|
| 31 |
Results From VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC)
|
Tabernero, J.
|
|
2011
|
47 |
S2 |
p. 5-
1 p.
|
artikel
|
| 32 |
Results of a Pilot External Quality Assurance Scheme for Somatic EGFR Mutation Testing in Non-Small Cell Lung Cancer Managed by EMQN, ESMO, ESP, and ETOP
|
Normanno, N.
|
|
2011
|
47 |
S2 |
p. 13-
1 p.
|
artikel
|
| 33 |
Reversal of Tamoxifen Resistance (Hormone Resistance) by Addition of Sirolimus (mTOR Inhibitor) in Metastatic Breast Cancer
|
Bhattacharvva, G.S.
|
|
2011
|
47 |
S2 |
p. 9-
1 p.
|
artikel
|
| 34 |
Safety and Efficacy of Panitumumab (pmab) in HPV Positive (+) and HPV Negative (−) Recurrent/metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Analysis of the Phase 3 SPECTRUM Trial
|
Vermorken, J.
|
|
2011
|
47 |
S2 |
p. 13-
1 p.
|
artikel
|
| 35 |
Synchronous Chemo-radiation Can Reduce Local Recurrence in Early Stage Breast Cancer: Results of the SECRAB Trial (ISRCTN: 84214355) Presented on Behalf of the SECRAB Steering Committee
|
Fernando, I.
|
|
2011
|
47 |
S2 |
p. 2-
1 p.
|
artikel
|
| 36 |
The EORTC 10041/BIG 03–04 MINDACT (Microarray in Node Negative and 1 to 3 Positive Lymph Node Disease May Avoid ChemoTherapy) Trial: Patients' Baseline Characteristics and Logistics Aspects After a Successful Accrual
|
Piccart, M.
|
|
2011
|
47 |
S2 |
p. 7-
1 p.
|
artikel
|
| 37 |
Unrecognised and Underprepared: an Exploratory Mixed Method Study of Informal Carers' Experiences of Supporting Someone Through Chemotherapy
|
Ream, E.
|
|
2011
|
47 |
S2 |
p. 14-15
2 p.
|
artikel
|
| 38 |
VANTAGE 014: Vorinostat (V) in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial
|
Krug, L.M.
|
|
2011
|
47 |
S2 |
p. 2-3
2 p.
|
artikel
|
| 39 |
Vemurafenlb Improves Overall Survival Compared to Dacarbazlne In Advanced BRAFV600E-mutated Melanoma: Updated Survival Results From a Phase III Randomised, Open-label, Multlcentre Trial
|
McArthur, G.
|
|
2011
|
47 |
S2 |
p. 14-
1 p.
|
artikel
|
| 40 |
Very Accelerated Radiotherapy (RT) Versus Concomitant Chemo-Radiotherapy (Ct-Rt) In Locally Advanced Head And Neck Cancer: Long Term Results From 2 Phases III GORTEC Randomized Trials
|
Bourhis, J.
|
|
2011
|
47 |
S2 |
p. 4-
1 p.
|
artikel
|
Tijdschrift beschrijving